You are on Trendlyne United States. Click here to go to India website or make United States as your default

222.05 1.80 (0.82%)

28.96% Gain from 52W Low

801.7K XNYS Volume

XNYS 19 Mar, 2025 5:30 PM (EDT)

Resmed Inc. Key Metrics

Select
All financials are in USD Million and price data in USD
VIEW MORE
High Financial Strength
72.2 / 100
Mid Valuation
37.0 / 100
Technically Neutral
38.9 / 100
Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

Resmed Inc. Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Jun '22Jun '23Jun '24Jun '25Jun '263k4k5k6kActual RevenueAvg. Estimate
Hit

Resmed Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Current EPS
6.9
Avg. Estimate
9.1
Low Estimate
8.9
High Estimate
9.2
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 31.5% in FY25

Consensus Recommendation

18 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Strong Sell6Hold3Buy8Strong Buy

The consensus recommendation from 18 analysts for Resmed Inc. is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Resmed Inc. Stock Analysis

Resmed Inc. stock analysis with key metrics, changes, and trends.

Resmed Inc. MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$4,685.3 M10.95%positive

Annual Revenue rose 10.95%, in the last year to $4,685.3 M. Its sector's average revenue growth for the last fiscal year was 8.73%.

Annual Net Profit$1,020.95 M13.75%positive

Annual Net Profit rose 13.75% in the last year to $1,020.95 M. Its sector's average net profit growth for the last fiscal year was 3.61%.

Price to Earning Ratio26.12-positive

Price to Earning Ratio is 26.12, lower than its sector PE ratio of 31.37.

Stock Price$222.0516.28%positive

Stock Price rose 16.28% and outperformed its sector by 8.62% in the past year.

Quarterly Revenue$1,282.09 M10.26%positive

Quarterly Revenue rose 10.26% YoY to $1,282.09 M. Its sector's average revenue growth YoY for the quarter was 8.58%.

Quarterly Net profit$344.62 M65.05%positive

Quarterly Net profit rose 65.05% YoY to $344.62 M. Its sector's average net profit growth YoY for the quarter was 27.3%.

Debt to Equity Ratio0.18-positive

Debt to Equity Ratio of 0.18 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)22.70 %22.7%positive

Return on Equity(ROE) for the last financial year was 22.7%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding47.98 %0.07%positive

Mutual Fund Holding increased by 0.07% in the last quarter to 47.98.

Promoter Share Holding0.57 %-0.01%negative

Promoter Share Holding decreased by 0.01% in the most recent quarter to 0.57%.

Interest Coverage Ratio28.67-positive

Interest Coverage Ratio is 28.67, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Institutional Holding61.37 %0%neutral

Institutional Holding remained the same in the last quarter at 61.37%.

VIEW LESS


Loading data..

Resmed Inc. - Company Profile

What does Resmed Inc. do?

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Resmed Inc. Management structure

All Gross Remunerations are in USD
Mr. Michael J. Farrell
Chairman of the Board and Chief Executive Officer
14.12 M
2024
Gross Remuneration
Year
Mr. Justin Leong
Chief Product Officer
3.6 M
2024
Gross Remuneration
Year
Mr. Kaushik Ghoshal
Chief Commercial Officer, Software as a Service Business (SaaS)
3.53 M
2024
Gross Remuneration
Year
Mr. Brett A. Sandercock
Chief Financial Officer and Principal Accounting Officer
3.23 M
2024
Gross Remuneration
Year
Mr. Michael J. Rider
Global General Counsel and secretary
2.15 M
2024
Gross Remuneration
Year
Mr. Robert Andrew Douglas
President and Chief Operating Officer
-
2024
Gross Remuneration
Year

Resmed Inc. Board of directors

All Gross Remunerations are in USD
Mr. Christopher DelOrefice
Director
-
2025
Gross Remuneration
Year

Resmed Inc. FAQ

How is Resmed Inc. today?
Resmed Inc. today is trading in the green, and is up by 0.82% at 222.05.
Resmed Inc. is currently trading up 0.82% on an intraday basis. In the past week the stock fell -1.66%. stock has been down -6.76% in the past quarter and rose 16.28% in the past year. You can view this in the overview section.